Algorae Pharmaceuticals has broadened its commercial footprint in Australia and New Zealand through key licensing agreements, while advancing its AI-driven drug discovery platform and strengthening leadership.
Algorae Pharmaceuticals has signed a binding term sheet with India’s Cadila Pharmaceuticals to introduce two generic medicines targeting cardiovascular and metabolic disorders in Australia and New Zealand.
Sigma Healthcare reports a robust FY25 performance post-merger with Chemist Warehouse Group, delivering strong revenue growth and upgraded synergy targets. The company signals continued expansion and efficiency gains heading into FY26.